PepGen Inc. (PEPG)
NASDAQ (NGS) NASDAQ (NGS) Primary 
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
PepGen Inc. (PEPG) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
The heavy selling pressure might have exhausted for PepGen (PEPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion in 2029. PGN-EDO53 is another EDO drug being developed by the company, with the goal of targeting 8% of DMD patients amenable to exon 53 skipping.
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, PepGen (PEPG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
